手机购彩

Hengrui Medicine Esketamine Hydrochloride Injection Approved for the First Time in China
Recently, Hengrui Medicine received the Drug Registration Approval issued by the State Drug Administration and approved the company's esketamine hydrochloride injection for sale.
2019-11-28
CCTV-1 "Life Circle" specially invited ESCORT researchers to talk about the breakthrough effect of Carelizumab in the treatment of esophageal cancer
China has always been a large country with esophageal squamous cell carcinoma (ESCC), and the number of patients accounts for more than half of the world. According to the cancer-related data published by the National Cancer Center in 2019, the mortality rate of esophageal cancer in China ranks second only to lung cancer, liver cancer and gastric cancer, ranking fourth. From November 7th to 9th, at the 15th World Congress of Esophageal Diseases (OESO International Conference), Professor Xu Jianming of the Fifth Medical Center of the General Hospital of the Chinese People's Liberation Army ...
2019-11-23
Hengrui Medicine and Lianyungang Broadcasting Media Group jointly hold the theme group day event
On November 8th, Hengrui Medicine and Lianyungang Broadcasting Media Group jointly held the theme group day event of “Don't forget the original intention to follow the party, keep in mind the mission and pursue the dream”, Tong Wei, Secretary of the Communist Party Committee, and Wan Zili, Deputy Director of the Broadcasting Media Group Leaders and young staff representatives from both units participated in the event
2019-11-15
Hengrui Medicine Indacaterol Maleate Inhalation Powder "Xinhua 4" Class Approved for the First Clinical Approval
Recently, Hengrui Medicine received the "Clinical Trial Notification" approved and issued by the State Drug Administration, and accepted the conclusion that Hengrui Medicine Indacaterol maleate inhalation powder is bioequivalent to the original drug, and approved the development. Clinical Trials. Indacaterol maleate inhalation powder is a new long-acting β2-receptor agonist intended for maintenance treatment of adult patients with chronic obstructive pulmonary disease (COPD). Chronic ...
2019-11-11
Hengrui Medicine introduces two patented products of CyclASol ™ and NOV03 from Novaliq, Germany
Recently, Hengrui Pharmaceuticals and Novaliq GmbH (hereinafter referred to as "Novaliq") reached an agreement. Hengrui Pharmaceuticals introduced CyclASol ™ (0.1% Spores A preparation) and NOV03 (perfluorohexyl octane), obtained the exclusive clinical development, production and marketing of these two patented products in China ...
2019-11-07
Hengrui Medicine letrozole tablets passed the consistency evaluation
Recently, Hengrui Medicine received the “Approval for Supplementary Drug Application” for letrozole tablets approved and issued by the State Drug Administration (hereinafter referred to as the “SFDA”). The drug passed the consistency evaluation of the quality and efficacy of generic drugs. Become the first domestic variety of the same variety to declare and pass the consistency evaluation. Letrozole is a selective, non-steroidal aromatase inhibitor, mainly used after menopause ...
2019-11-06
CCTV Dialogue: Chairman of Hengrui Medicine on China's Pharmaceutical Innovation
On the evening of November 3, the CCTV talk show "Dialogue" was broadcast on the CCTV Finance Channel. The theme of this episode was "Innovative Drug Acceleration". Sun Piaoyang, Chairman of Hengrui Medicine, was invited to participate. Investors jointly discussed in depth the advantages of innovative drugs, industrialization of innovative drugs, sources of funding for research and development of innovative drugs, and the impact of national policies on innovative drugs. Dialogue is ...
2019-11-05
Wu Jincheng, director of Shanghai Economic and Information Commission, and his party investigated Hengrui Medicine
On the afternoon of October 31, Wu Jincheng, director of the Shanghai Economic and Informatization Commission, and his party visited Hengrui Medicine Shanghai Clinical Research Headquarters for investigation. The chairman and deputy general managers Zhang Lianshan and Dai Hongbin received the investigation.
2019-11-05
上一页 1 2 3 4 5 6 ... 12 下一页 Total 95 Records Previous 1 2 3 4 5 6 ... 12 Next